Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Anlotinib and Chemotherapy in First-Line NSCLC
NCT04846452Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04846452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846452.